In spite of the drug's toxicity, cyclosporine A (CsA) is largely used in several diseases, including dermatological pathologies, with beneficial results. In dermatology cyclosporin-A reduces the severity of psoriasis symptoms, Bechet's disease, pyoderma gangrenosum, blistering disorders, aftous stomatitis, lichen planus, atopic dermatitis, alopecia and allergic contact dermatitis.
Cyc1osporin A (CsA) has been in clinical use for some decades, primarily for the prevention and treatment of organ transplant rejection and graftversus-host disease. In more recent years,Cyc1osporin has been recognized as beneficial in the treatment of dermatologic diseases, such as: psoriasis, lichen planus, Behcet disease, atopic dermatitis, pyoderma gangrenosum and epidermolysis bullosa acquisita. Above all, Cyc1osporin is an important therapeutic modality for several dermatologic diseases that are refractory to other agents.
Nevertheless, drug toxicity, high rates of relapse after treatment cessation and high cost have limited its use. Long-term systemic administration of cyc1osporin has been noted to produce harmful but reversible systemic side effects such as anemia, bone marrow hypoplasia, lymphopenia, granulomatous hepatitis, and proximal renal tubular cell damage (1) (2) . This draw-back has led to the exploration of investigations using CsA in various drug target system to achieve local immune suppression. Many investigators have studied local immunosuppression with topical CsA (3) (4) . Limited effect of topical cyc1osporin has been seen in treatment of psoriasis, contact dermatitis and atopicdermatitis (5) (6) .Whereas it has been shown to be effective in a variety of oral mucosal disorders (7) (8) (9) .
Clinical trials with topical cyc1osporin for disease that respond to systemic administration of drug suggest that the ineffectiveness of topical CsA may be attributed to insufficient absorption by the skin (5, 7, (10) (11) . In recent year, various formulations oftopical CsA have being investigate to produce a formulation with superior efficacy and reduced or minimal systemic effects. The major barrier to transdermal absorption of any drugs is the stratum corneum. It contains 10-15 layers of devitalized, keratinized cells that are densely packed and separated by lipid bilayers. Other layers beneath the stratum corneum lie in a hydrophilic, acqueous environment. Both the solubility of the compound and the polarity of the carriers appear to influence levels of transdermal drug delivery. CsA is a hydrophobic cyclic undecapeptide with a molecular weight of 1202.6 and readly penetrates the lipid bilayers of the stratum corneum in a appropriate formulations (12) (13) . Recently, various formulations of topical CsA (tCsA) have being investigated to produce a formulation with superior efficacy and reduced systemic side effects (12) .
Futhermore, CsA is metabolized predominantly in the liver by the hepatic cytochrome P-450 (III A isoform) (14) , generating several immunosuppressive metabolites (15) . The presence of a P-450enzyme system, in the skin, generating these metabolites had not been demonstrated yet. Besides, it can be speculated that CsA is neutralized in the skin by some enzyme system, or by binding to a compartment in which CsA does not exert any immunosuppressive action. Actually, no data are available to substantiate these hypothesis (13) .
The immunosuppressive macrolides are a novel class of compounds sharing a macrolide-like structure and potent immunosuppressive activity in vitro and in vivo (16) (17) . Macrolide immunosuppressants are also effective in dermatological diseases. They have similar sideeffects but they differ in their structure.
Tacrolimus (FK 506), the best know substance of this group, is registered in many countries for the prevention of transplant rejection. Tacrolimus is 10-100 times more potent than Cyclosporin A (18) . Clinical trials have demonstrated the efficacy of FK506 for atopic dermatitis, allergic contact dermatitis, erosive mucosal lichen planus and pyoderma gangrenosum (17) (18) . Although topical tacrolimus has not been studied sufficiently in treating psoriasis. The ascomycin derivate (ASM 981) has many of the properties ofFK 506. It had topical potency equal tacrolimus despite a several fold lower potency for inhibiting swine T cells in vitro, consistent with superior skin penetration, but less data are available at present (19) . Rapamycin is structurally related to FK 506 but has other biological effects since its molecular actions involve different biochemical pathways (17) . Cyclosporin or rapamycin are capable of inhibiting local inflammatory/immune responses by topical application to skin tissue in vivo. Rapamycin was particularly efficacious during the late local inflammatory-immune phase, on the other hand cyclosporin was particularly efficacious during the early local inflammatory-immune phase (3).
Immunosuppressive macrolides have been used topically in various clinical studies. Administration oftopical CsA in various experimental models has been theorized to induce localized site-specific immunosuppression (SITE). Recently, the cellular mechanisms by which topical cyclosporin A (tCsA) induces site-specific immunosuppression has been investigated. The mechamism of SITE has been postulated to involved down-regulation of target tissue antigen expression, in particular, the local expression of MHC class I and class II surface molecules or specific inhibition oflocal preactivated or activated immunocytes, particularly, Th l, Th2 and cytotoxic T-cell lymphocytes (20) .
DERMATOLOGIC INDICATIONS FOR TOPICAL IMMUNOSUPPRESSIVE
MACROLIDE Psoriasis-Psoriasis is one of the more common forms of chronic dermatitis in the world. Actually, there is no cure for psoriasis but there are many different treatment options to reduce the severity of symptoms.
Oral cyclosporin therapy has been reported to be effective in severe or recalcitrant psoriasis and also in erythrodermic psoriasis, von Zumbusch's pustolar psoriasis, acrodermatitis continua, psoriatic arthritis and nail disease of psoriasis. Cyclosporin inhibits lymphokine secretion such as interferon-' Y and IL 2, which may have a role in the pathogenesis of psoriasis. Cyclosporin causes a selective T-cell depletion that correlates with a reduction in psoriasis disease". However, systemic administration of cyclosporin A is associated with serious side effects. It would be desirable to treat psoriasis topically. Several clinical studies have been done on the effectiveness or lack effects of topical cyclosporin A in psoriasis (22) (23) (24) . No one has yet convincingly shown clinical activity oftopical cyclosporin A in psoriasis, however (25) (26) . Intralesional injection of cyclosporin does eradicate psoriatic lesions, so it is likely that the ineffectiveness of the topical formulations results from low level skin permeability (27) (28) .
Behcet Disease -Cyclosporin is effective in controlling the ocular complications and mucocutaneous and musculoskeletal manifestations of Behcet disease (29) . Ergun et al. (30) , reported beneficial results with topical cyclosporin in treating oral ulcers of Behcet's disease.
Pyoderma Gangrenosum -Pyoderma Gangrenosum has been treated successfully with cyclosporin. Theissen (31) report on a patient presenting with recalcitrant pyoderma gangrenosum who was treated successfully by topical application of cyclosporin A. In another study, a patient had improvement within 2 weeks after intralesional injection of cyclosporin (32) .
Blistering disorders -Topical application of cyclosporin was successful in managing benign familiar pemphigus (Hailey-Hailey disease) (33), cicatricial pemphigoid (34) and oral pemphigus (35) .
Aphthous Stomatitis -Eisen and colI. (7) , reported conflicting results with topical cyclosporin in treating aphthous stomatitis. The pathogenesis of aphthous stomatitis is unknow, evidence in some cases suggests an immunologic basis; the different origins of this disorder may be responsible for patients' inconsistent responses to treatment with topical cyclosporin.
Lichen Planus -Topical cyclosporin has been studied in the treatment of oral lichen planus with positive results in several reports (7) (8) (36) (37) (38) (39) (40) . Pre-and post-therapy biopsies have revealed decreased T cell infiltrate and reduced expression of ICAM -1 and HLA -DRafter topical cyclosporin (36) . Topical cyclosporin therapy may be more effective in oral lichen planus than in cutaneous lichen planus because of the relatively higher absorption through mucous membranes (29) .
Atopic dermatitis -The efficacy of local applications of 10% cyclosporin gel was studied in a randomised double-blind placebo-controlled trial in atopic dermatitis (41) . However, in another study (13) , no significant improvement was found in 16 atopic dermatitis patients after topical cyclosporin therapy. Studies evaluating the use of topical tacrolimus showed that it is effective in the treatment of atopic dermatitis with no evidence thus far of systemic adverse effects (42) . Tacrolimus ointment is the first in a class of topical immunodulators. Actually, Tacrolimus ointment was safe and effective in phase 2/early phase 3 studies (43); significant reduction of atopic dermatitis was observed in the majority of patients treated with tacrolimus ointment. Its mechanism of action is based on calcineurin inhibition, which results in suppression of antigen specific T-cell activation and inhibition of inflammatory cytokine release.
Alopecia -Cyclosporin seems to have an immunomodulatory effect on alopecia areata. Mixed results have been reported with cyclosporin applied topically in the treatmentofalopecia areata, probably because of the lack of pronounced absorption (44).
Maurer et al. (45) , demostrate that topical CsA and Tacrolimus provide relative protection from alopecia and follicle dystrophy induced by cyclophosphamide, possibly by favoring the distrophic anagen pathway of follicle response to chemical damage.
Allergic Contact dermatitis -No significant improvement was found in allergic contact dermatitis patients in treatment with topical cyclosporin (13, 46) .
MECHANISM OF ACTION
Systemic administration of CsA modulates the immune response by the activation of helper T cells, which, by secretion of cytokines, control the activation of both cellular and humoral immunity.
CsA acts by inhibiting the release of cytokine cellular growth factors such as interleukin (IL)-2, IL-3, IL-4, granulocyte colony stimulating factors (CSFs), macrophage-CSF, Interferon-v and tumor necrosis factor -u. In absence ofIL-2, the primary T-lymphocyte growth factors, antigen-stimulated T cells do not undergo mitogenesis. Therefore, treatment with cyclosporin prevents the generation of an antigen-specific population ofT cells capable of coordinating an immune response. Besides, CsA take effect blocking the inflammatory immune cascade and easying allograft acceptance by inhibiting the CD4 (+) MHC class II responsive Th cells that are the primary modulators ofT cellmediated immune response and permitting the acti vation and amplification of suppressor T lymphocytes
